Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Down 28.4% in May

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 28,300 shares, a decrease of 28.4% from the May 15th total of 39,500 shares. Based on an average daily volume of 138,600 shares, the days-to-cover ratio is currently 0.2 days.

Appili Therapeutics Stock Performance

Shares of APLIF remained flat at $0.03 during mid-day trading on Friday. 7,000 shares of the company’s stock were exchanged, compared to its average volume of 204,918. The firm has a market capitalization of $3.73 million, a price-to-earnings ratio of -0.77 and a beta of -0.53. Appili Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.08. The business’s 50 day moving average price is $0.03 and its two-hundred day moving average price is $0.03.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.